Related Experiment Video
Updated: Aug 1, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
The Potential of Cilostazol in Interventional Cardiology
1Department of Cardiology, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3, Nakamichi, Higashinari, Osaka-City, Osaka 537-1181, Japan. oscmed1@skyblue.ocn.ne.jp
Abstract:
Cilostazol, an antiplatelet agent developed in Japan, has been demonstrated to have the potential to reduce restenosis after percutaneous transluminal coronary angioplasty (PTCA). Unlike conventional antiplatelet agents, cilostazol has several favorable properties in reducing restenosis. Besides the vasodilatory effect, cilostazol directly inhibits smooth muscle proliferation and may enhance reendothelialization after PTCA. Although the magnitude of prevention of restenosis may differ with the PTCA device used, cilostazol appears quite promising as a pharmacologic treatment adjunct to PTCA.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiac Catheterization I: Pre-Procedure Overview
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care

